CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.
about
Optimal starting point for antiretroviral HIV treatment in a town in Cameroon: a randomised controlled studyNew indicators for delay in initiation of antiretroviral treatment: estimates for CameroonCould early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.Sub-Saharan African migrants living with HIV acquired after migration, France, ANRS PARCOURS study, 2012 to 2013.Estimating time of HIV-1 infection from next-generation sequence diversity.Race and CD4+T-cell count in HIV prognosis and treatment
P2860
CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@en
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@nl
type
label
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@en
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@nl
prefLabel
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@en
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@nl
P2093
P2860
P1433
P1476
CD4 cell eligibility threshold ...... tment in HIV-1 seroconverters.
@en
P2093
Agence Nationale de Recherches sur le Sida (ANRS) 1220 Primo-CI Study Group
Albert K Minga
André Inwoley
Arlette A Emième
Charlotte Lewden
Germain I Bomisso
Roger Salamon
Thomas-d'aquin Toni
Vincent Yapo
P2860
P304
P356
10.1097/QAD.0B013E32834625D3
P407
P577
2011-03-01T00:00:00Z